UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Journal of clinical oncology, 2006-01, Vol.24 (1), p.25-35

2006

Volltextzugriff (PDF)

Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

Journal of clinical oncology, 2007-03, Vol.25 (9), p.1107-1113

2007

Volltextzugriff (PDF)

Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults

Clinical cancer research, 2008-11, Vol.14 (21), p.7102-7109

2008

Volltextzugriff (PDF)

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

Frontiers in pharmacology, 2021-09, Vol.12, p.711813-711813

2021

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

Clinical cancer research, 2006-10, Vol.12 (20), p.6073-6078

2006

Volltextzugriff (PDF)

Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential

Therapeutic Advances in Medical Oncology, 2012-01, Vol.4 (1), p.9-18

2012

Volltextzugriff (PDF)

Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non–Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy

Journal of clinical oncology, 2007-08, Vol.25 (23), p.3448-3455

2007

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7871-7880

2005

Volltextzugriff (PDF)

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

Targeted oncology, 2011-06, Vol.6 (2), p.119-124

2011

Volltextzugriff (PDF)

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

The New England journal of medicine, 2011-05, Vol.364 (19), p.1817-1825

2011

Volltextzugriff (PDF)

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

The lancet oncology, 2022-11, Vol.23 (11), p.1367-1377

2022

Volltextzugriff (PDF)

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development

Expert opinion on drug metabolism & toxicology, 2010-08, Vol.6 (8), p.1005-1015

2010

Volltextzugriff (PDF)

Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis

JAMA : the journal of the American Medical Association, 2010-05, Vol.303 (17), p.1729

2010

Volltextzugriff (PDF)

Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis

JAMA : the journal of the American Medical Association, 2004-07, Vol.292 (4), p.470

2004

Volltextzugriff (PDF)

Phase I evaluation of seliciclib ( R -roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

European journal of cancer (1990), 2010-12, Vol.46 (18), p.3243-3250

2010

Volltextzugriff (PDF)

Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis

European journal of cancer (1990), 2013-05, Vol.49 (7), p.1565-1577

2013

Volltextzugriff (PDF)

Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1070-1070

2021

Volltextzugriff (PDF)

Postoperative irinotecan in resected stage II–III rectal cancer: final analysis of the French R98 Intergroup trial

Annals of oncology, 2015-06, Vol.26 (6), p.1208-1215

2015

Volltextzugriff (PDF)

Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD9-08-PD9-08

2022

Volltextzugriff (PDF)

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Oncology, 2011-01, Vol.80 (5-6), p.301-306

2011

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

Investigational new drugs, 2008-02, Vol.26 (1), p.35-43

2008

Volltextzugriff (PDF)

Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial

Gynecologic oncology, 2019-01, Vol.152 (1), p.68-75

2019

Volltextzugriff (PDF)

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 – REGOLD

Journal of geriatric oncology, 2020-11, Vol.11 (8), p.1255-1262

2020

Volltextzugriff (PDF)

Dose intensity and toxicity associated with Taxotere formulation: a retrospective study in a population of breast cancer patients treated with docetaxel as an adjuvant or neoadjuvant chemotherapy

Anti-cancer drugs, 2015-10, Vol.26 (9), p.984-989

2015

Volltextzugriff (PDF)

Pharmacocinétique (PK) et pharmacodynamie (PD) de l’imatinib (Glivec®)

Therapie, 2007-03, Vol.62 (2), p.87-90

Delbaldo, Catherine

2007

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(35)

Publikationsform

Sprache

Englisch
(40)
Französisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(33)
Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Oncology
(22)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Tumors
(18)
Middle Aged
(17)
Aged
(16)
Female
(16)
Adult
(15)
Male
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Treatment Outcome
(10)
Aged, 80 And Over
(8)
Antineoplastic Agents - Therapeutic Use
(7)
Chemotherapy
(7)
Gastroenterology. Liver. Pancreas. Abdomen
(7)
Neoplasms - Drug Therapy
(7)
Pharmacology. Drug Treatments
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential

Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non–Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy

Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development

Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis

Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis

Phase I evaluation of seliciclib ( R -roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis

Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial

Postoperative irinotecan in resected stage II–III rectal cancer: final analysis of the French R98 Intergroup trial

Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 – REGOLD

Dose intensity and toxicity associated with Taxotere formulation: a retrospective study in a population of breast cancer patients treated with docetaxel as an adjuvant or neoadjuvant chemotherapy

Pharmacocinétique (PK) et pharmacodynamie (PD) de l’imatinib (Glivec®)

Suchergebnisse filtern